75F40126F19009↗
Deloitte Consulting LLP received this contract from Fda Office of Acq Grant Svcs, Food and Drug Administration: $1.43M obligated so far for special studies/analysis- regulatory. It runs to 2027-08-20, or to 2027-09-29 if every option is exercised.
Key facts · data as of Oct 26, 2026
- Recipient
- Deloitte Consulting LLP
- Awarding agency
- Food and Drug Administration (Department of Health and Human Services)
- Contracting office
- Fda Office of Acq Grant Svcs (75F401)
- Obligated to date
- $1.43M
- Potential value
- $1.43M
- Ends
- 2027-08-20
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 26, 2026.
Cite this page: SpendQuery, Award 75F40126F19009, data as of Oct 26, 2026, https://spendquery.com/award?id=CONT_AWD_75F40126F19009_7524_75F40122A00018_7524
Deloitte Consulting LLP: all federal awards · Department of Health and Human Services: spending · Fda Office of Acq Grant Svcs: what it buys · The follow-on: recompete brief
EO 14398-FIRM-FIXED-PRICE BPA CALL UNDER BPA 75F40122A00018 TO PROVIDE RESEARCH, ANALYTICAL, LABELING STRATEGY, STAKEHOLDER ENGAGEMENT, PROJECT MANAGEMENT, AND RELATED SUPPORT SERVICES FOR FDA CDER'S DRUG LABELING INITIATIVE AND DRUG REPURPOSING
Up for re-bid: ends 2027-08-20. Recompete brief →
What it is
- Product or service
- Special Studies/Analysis- Regulatory (PSC B528)
- Industry
- All Other Professional, Scientific, and Technical Services (NAICS 541990)
- Contracting office
- Fda Office of Acq Grant Svcs (75F401)
- Competition
- Not competed under simplified acquisition · 1 offer received
- Pricing
- Firm fixed price
- How it was bought
- Blanket purchase agreement (BPA) · under 75F40122A00018
- Where the work is
- Arlington, VA · district VA-08
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
1 action since 2026-08-21. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-08-21 | 0 | $1.43M | EO 14398-FIRM-FIXED-PRICE BPA CALL UNDER BPA 75F40122A00018 TO PROVIDE RESEARCH, ANALYTICAL, LABELING STRATEGY, STAKEHOLDER ENGAGEMENT, PROJECT MANAGEMENT, AND RELATED SUPPORT SERVICES FOR FDA CDER'S DRUG LABELING INITIATIVE AND DRUG REPURPOSING |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-26). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗